INDEX

Note: Page numbers of article titles are in boldface type.

Abdominal/pelvic sepsis, cephalosporins for, 713–714
Acinetobacter, antibiotic susceptibility of, 681
Acne, clindamycin for, 852–853
Aerobic gram-positive cocci, clindamycin spectrum of activity against, 848
Allergic reactions, to antibiotic therapy, 935–942
Amanadine, dosing of, in renal failure, 921
Amebiasis, metronidazole for, 863
Amikacin, chemical configuration of, 765
gram-negative bacterial in vitro susceptibility to, 763
in hepatic disease, pharmacokinetics of, 904
in renal failure, dosing of, 921
Aminoglycosides, 761–787
adverse reactions to, 775–777
antimicrobial activity of, 762–765
antimicrobial synergy of, 766–767
chemical configurations of, 764–765
clinical use of, 777–779
curare-like effect of, 777
drug interactions with, 777
efficacy of, animal models of, 779–780
clinical studies of, 780–781
empiric therapy with, 778–779
for obese patients, dosing weight correction factor for, 774
gram-negative bacterial resistance to, mechanisms of, 767–768
historical information on, 761
in hepatic disease, pharmacokinetics of, 904
mechanism of action of, 767
microbiology of, 762–768
modifying factors in, 766
once-daily dosing of, 779–781
DREM in, 924–928
serum concentration in, 926
pharmacodynamics of, 768–769
pharmacokinetics of, 769–775
absorption, 770
distribution, 770–771
elimination, 771–773
in hepatic disease, 904
therapeutic monitoring, 773–775
time or dose dependency, 770
prophylaxis with, 777–778
safety profile of, 775–777
susceptibility testing of, 762
therapeutic alternatives to, 779–781
therapeutic concentrations of, 773
toxicity of, animal models of, 780
clinical studies of, 781
Amoxicillin/clavulanic acid, in vitro activity and cost of, 698
indications for, 702
Ampicillin, in hepatic disease, 903
pharmacokinetics of, 905
with sulbactam, in vitro activity and cost of, 698
indications for, 702
Anaerobes, clindamycin spectrum of activity against, 847–848
metronidazole spectrum of activity against, 858, 860–861
Animal bite, antibiotic therapy for, in allergic patient, 937
Animal toxicity, of carbapenems, 750–751
Antibiotic(s), in hepatic disease, 895–917
in renal failure, changing dose or dosing interval in, 924–925
dosing of, 919–933
DREM system for, 920–922
partial renal elimination of, DREM in, 924
serum concentration-time curve for, one-compartment model of, 896
two-compartment model of, 898
therapy with, in allergic patient, 935–942
choice of, 936–941
manifestations of, 936
Antifungals, in hepatic disease, pharmacokinetics of, 904
Anti-HIV drugs, dosing of, in renal failure, 922
Anti-infective agents, and hepatic disease, 895–917
   pharmacokinetics in, 904–910
Antivirals, in hepatic disease, 903
   pharmacokinetics of, 904
Azithromycin, 803–815
   allergy to, alternatives for, 940
   antimicrobial spectrum of, 804–805
   clinical pharmacokinetics of, 805–809
   clinical use of, 811–813
   experimental therapy with, 813
   in hepatic disease, pharmacokinetics of, 909
   in vitro activities of, 806–807
   safety profile of, 809–811
Azlocillin, pharmacologic characteristics of, 683
AZT, in hepatic disease, pharmacokinetics of, 904–905
Aztreonam, 733–743
   antimicrobial spectrum of, 733–734
   clinical pharmacokinetics of, 734–738
   clinical spectrum of, 739
   clinical use of, 738–741
   concentrations in body fluids/tissues, 737
   in hepatic disease, pharmacokinetics of, 905
   in vitro activity of, 735
   safety profile of, 738
Babesiosis, clindamycin for, 854
Bacteremia, aztreonam for, 740
cephalosporins for, 715
Bacteria, gram-negative. See Gram-negative bacteria.
   gram-positive. See Gram-positive bacteria.
Bacterial meningitis, carbapenems for, 754
Bacterial prostatitis, quinolones for, 875–876
Bacterial vaginosis, clindamycin for, 853
metronidazole for, 863
Beta-lactam antibiotics, 745–759
   in hepatic disease, 903–911
   pharmacokinetics of, 905
   susceptibility of gram-negative rods to, 681
Beta-lactamase inhibitor combinations, 695–704
   antimicrobial spectrum of, 697–699
   clinical pharmacokinetics of, 699–700
   clinical use of, 701–703
   in vitro activity and cost of, 698
   indications for, 702
   safety profile of, 700–701
Beta-lactamase resistance, development of, 696
Bone/joint infections, aztreonam for, 741
cephalosporins for, 713–714
quinolones for, 880–881
Carbapenems, 745–759
   adverse reactions to, 750–753
   animal toxicity of, 750–751
   antimicrobial spectrum of, 746–747
   central nervous system reactions to, 751
   clinical pharmacokinetics of, 746
   clinical use of, 753–756
   dosing recommendations for, 749–750
   gastrointestinal reactions to, 751–752
   hypersensitivity reactions to, 752
   laboratory adverse experiences with, 752–753
   metabolism of, 746–748
   plasma kinetics, elimination, and tissue penetration of, 748–749
   renal safety of, 752
Carbenicillin, in hepatic disease, pharmacokinetics of, 905
   indanyl, indications, dosing, and preparations of, 684
   pharmacologic characteristics of, 683
Carboxypenicillins, antipseudomonal, antimicrobial spectrum of, 680–682
Cefepime, 721–732
   antimicrobial spectrum of, 721–723
   clinical use of, 729
   comparative antimicrobial activity of, 724
   dosing recommendations for, 725
   in vitro activity of, 722
   pharmacokinetics of, 725–728
   potential resistance of, 723–725
   safety profile of, 728–729
   structure and urinary metabolites of, 728
   therapeutic alternatives to, 730
Cefoperazone, adverse effects of, 711
   clinical use of, 716
   comparative antimicrobial activity of, 724
   in vitro activity of, 735
   pharmacokinetics of, 726
   in hepatic disease, 905
   spectrum of activity of, 708–709
Cefotaxime, adverse effects of, 711
   allergy to, alternatives for, 939
   clinical use of, 712–715
   comparative antimicrobial activity of, 724
   in vitro activity of, 735
   pharmacokinetics of, 726
   in hepatic disease, 906
   spectrum of activity of, 708–709
Ceftazidime, adverse effects of, 711
   allergy to, alternatives for, 939
clinical use of, 716
comparative antimicrobial activity of, 724
in vitro activity of, 735
pharmacokinetics of, 726
  in hepatic disease, 906
spectrum of activity of, 708–709
Ceftizoxime, adverse effects of, 711
allergy to, alternatives for, 939
clinical use of, 712–715
spectrum of activity of, 708–709
Ceftriaxone, adverse effects of, 711
allergy to, alternatives for, 939
clinical use of, 717
comparative antimicrobial activity of, 724
pharmacokinetics of, 726
in hepatic disease, 906
spectrum of activity of, 708–709
Central nervous system, infections of, aztreonam for, 741
cephalosporins for, 713, 715
reactions to carbapenems, 751
Cephalosporin(s), allergy to, alternatives for, 939
fourth-generation, comparative antimicrobial activity of, 724
pharmacokinetics of, 726
susceptibility breakpoints for, 723
third-generation, 705–719
adverse effects of, 711
antimicrobial spectrum of, 705–707
clinical use of, 712–717
comparative antimicrobial activity of, 724
dosing recommendations for, 709
in vitro activity of, 735
pharmacokinetics of, 707–709, 726
route of administration of, 706
safety profile of, 710–712
spectrum of activity of, 708–709
structure of, 706
susceptibility breakpoints for, 723
therapeutic alternatives to, 716–717
Chloramphenicol, in hepatic disease, 911–912
pharmacokinetics of, in hepatic disease, 907
Ciprofloxacin, pharmacokinetics of, 873
  in hepatic disease, 907
spectrum of in vitro activity of, 872
susceptibility of gram-negative rods to, 681
Clarithromycin, 803–815
allergy to, alternatives for, 940
antimicrobial spectrum of, 804–805
clinical use of, 811–813
experimental therapy with, 813
in vitro activities of, 806–807
pharmacokinetics of, 805–809
  in hepatic disease, 909
safety profile of, 809–811
Clindamycin, 845–867
adverse effects of, 848–850
allergic reactions to, 849
dosage and route of administration, 854–855
drug interactions with, 850
  in hepatic disease, 912–913
pharmacokinetics of, 907
indications for, 850–854
acne, 852–853
  babesiosis, 854
bacterial vaginosis, 853
decubitus ulcers, 852
diabetic foot ulcers, 852
endocarditis prophylaxis, 853
endophthalmitis, 853
head and neck surgery, 853
intra-abdominal infections, 850–851
malaria, 854
odontogenic infections, 851–852
osteomyelitis, 853
pelvic infections, 851
pleuropulmonary infections, 852
Pneumocystis carinii infections, 854
skin/soft tissue infections, 852
Toxoplasma infections, 854
upper respiratory tract infections, 851
mechanisms of activity and resistance, 847
pharmacology of, 845–847
spectrum of activity of, 847–848
structure of, 845–846
use in pregnancy and nursing mothers, 855
Clostridium difficile diarrhea, metronidazole for, 861
Crohn’s disease, metronidazole for, 861
Dapsone, in hepatic disease, pharmacokinetics of, 907
Decubitus ulcers, clindamycin for, 852
Diabetic foot ulcers, clindamycin for, 852
Diarrhea, Clostridium difficile, metronidazole for, 861
  with clindamycin, 849
Dosing in Renopathy by Easy-to-Use Multipliers (DREM) system, 920–922
Doxycycline, antibiotic sensitivities of, 791
DREM (Dosing in Renopathy by Easy-to-Use Multipliers) system, 920–922
in once-daily dosing of aminoglycosides, 924–928
mathematical derivation of multipliers in, 933
simplification of, 922–924
Drug(s), hepatic elimination of, classification of, 901
Drug(s) (Continued)

in hepatic disease, capacity-limited, 902
clearance of, 897
hepatic, 899–901
systemic, 898–899
flow-dependent, 901–902
intermediate extraction ratio of, 902–903

Endocarditis, antibiotic therapy for, in allergic patient, 937
prophylaxis for, clindamycin for, 853
Endophthalmitis, clindamycin for, 853
Enoxacin, pharmacokinetic parameters of, 873
spectrum of in vitro activity of, 872
Enterobacter, antibiotic susceptibility of, 681
Erythromycin, allergy to, alternatives for, 940
in hepatic disease, pharmacokinetics of, 909
in vitro activities of, 806–807
Escherichia coli, antibiotic susceptibility of, 681

Fleroxacin, pharmacokinetics of, 873
in hepatic disease, 908
spectrum of in vitro activity of, 872
Fluoroquinolones. See also Quinolones.
in hepatic disease, 913–914
pharmacokinetics of, 907
pharmacokinetics of, 873
spectrum of in vitro activity of, 872
structure of, 870
Foscarnet, dosing of, in renal failure, 922

Gancyclovir, dosing of, in renal failure, 922
Gastrointestinal infections, quinolones for, 876–878
tetracyclines for, 799
Gastrointestinal reactions, to carbapenems, 751–752
to metronidazole, 859
Gentamicin, chemical configuration of, 764
dosing of, in neonates, 772
in renal failure, 921
once-daily, serum concentration in, 927
gram-negative bacterial in vitro susceptibility to, 763
in hepatic disease, pharmacokinetics of, 904
Gentourinary tract infection, cephalosporins for, 713–715
Giardiasis, metronidazole for, 863
Gonorrhea, aztreonam for, 741
Gram-negative bacteria, aminoglycosides for, 762–763
in vitro susceptibility to amikacin, 763
in vitro susceptibility to gentamicin, 763
resistance to aminoglycosides, mechanisms of, 767–768
Gram-positive bacteria, aminoglycosides for, 763–765
Half-life, of antibiotics, in hepatic disease, 896–897
Head and neck surgery, clindamycin for, 853
Helicobacter pylori, metronidazole for, 862
Hepatic disease, altered drug disposition in, 900
anti-infective agents and, 895–917
pharmacokinetics of, 904–910
antivirals in, 903
beta-lactams in, 903–911
chloramphenicol in, 911–912
clindamycin in, 912–913
fluoroquinolones in, 913–914
isoniazid in, 914
pharmacokinetic principles in, 896–903
capacity-limited drugs, 902
drug clearance, 897
flow-dependent drugs, 901–902
half-life, 896–897
hepatic clearance, 899–901
intermediate extraction ratio, 902–903
systemic clearance, 898–899
volume of distribution, 897–898
rifampin in, 914
Human bite, antibiotic therapy for, in allergic patient, 937
14-Hydroxyclarithromycin, in vitro activities of, 806–807
Hypersensitivity reactions, with clindamycin, 849
Imipenem, antimicrobial spectrum of, 747
dosing recommendations for, 749–750
Imipenem-cilastatin, comparative efficacy of, 755
dosing regimens for, 750
peripheral penetration of, 749
pharmacokinetics of, 748
in hepatic disease, 907
Indanyl carbenicillin, indications, dosing, and preparations of, 684
Intra-abdominal infections, aztreonam for, 740–741
carbapenems for, 753
INDEX 947

clindamycin for, 850–851
Intravenous line sepsis, cephalosporins for, 714–715
Isoniazid, in hepatic disease, 914
pharmacokinetics of, 908
Itraconazole, in hepatic disease, pharmacokinetics of, 904

Kanamycin, dosing of, in renal failure, 921
Klebsiella, antibiotic susceptibility of, 681

Liver, anti-infective agents and, 895–917
Local reactions, with clindamycin, 849
Lomefloxacin, pharmacokinetic parameters of, 873
spectrum of in vitro activity of, 872
Lower respiratory tract infections, aztreonam for, 740
carbapenems for, 753–754
Lyme disease, cephalosporins for, 714

Macrolide antibiotics, alternatives to, 812, 940
in hepatic disease, pharmacokinetics of, 909
in vitro activities of, 806–807
indications for, 812
Malaria, clindamycin for, 854
Meningitis, antibiotic therapy for, in allergic patient, 937
bacterial, carbapenems for, 754
Meropenem, antimicrobial spectrum of, 747
dosing recommendations for, 750
pharmacokinetics of, 748
Metronidazole, 845–867
absorption of, 856
adverse effects of, 858–860
carcinogenicity concerns about, 860
clinical use of, 860–863
amebiasis, 863
anaerobic infections, 860–861
bacterial vaginosis, 863
Clostridium difficile diarrhea, 861
Crohn’s disease, 861
giardiasis, 863
Helicobacter pylori, 862
perioperative, 863
tetanus, 862
trichomoniasis, 863
distribution and tissue penetration of, 857
dosage and route of administration of, 864
in hepatic disease, pharmacokinetics of, 909
interactions with alcohol, drugs, and laboratory tests, 859
mechanisms of activity and resistance, 857
metabolism and excretion of, 857
mutagenicity concerns about, 860
pharmacology of, 856–857
spectrum of activity of, 858
structure of, 846
use in pregnancy and nursing mothers, 864

Mezlocillin, in hepatic disease, pharmacokinetics of, 907
indications, dosing, and preparations of, 685
microbial susceptibility to, 681
pharmacologic characteristics of, 683
Minocycline, antibiotic sensitivities of, 791
Miomycin, in hepatic disease, pharmacokinetics of, 909
Nafillin, in hepatic disease, pharmacokinetics of, 907
Nalidixic acid, 869–894. See also Quinolones.
Nephrotoxicity, with aminoglycosides, 775–776
Netilmicin, chemical configuration of, 765
in hepatic disease, pharmacokinetics of, 904
in renal failure, dosing of, 921
Neurologic adverse effects, of metronidazole, 858–859
Neutropenia, febrile, antibiotic therapy for, in allergic patient, 937
carbapenems for, 754
quinolones for, 883–884
Norfloxacin, pharmacokinetics of, 873
in hepatic disease, 908
spectrum of in vitro activity of, 872
Nursing mothers, clindamycin use in, 855
metronidazole use in, 864

Obese patients, aminoglycosides for, dosing weight correction factor for, 774
Obstetric/gynecologic infections, carbapenems for, 753
Odontogenic infections, clindamycin for, 851–852
Ofloxacin. See also Quinolones.
pharmacokinetics of, 873
in hepatic disease, 908
spectrum of in vitro activity of, 872
Osteomyelitis, clindamycin for, 853
Ototoxicity, with aminoglycosides, 776–777

Para-aminosalicylic acid, in hepatic disease, pharmacokinetics of, 910
Pefloxacin, in hepatic disease, pharmacokinetics of, 908
Pelvic infections, aztreonam for, 740–741
clindamycin for, 851
Pelvic inflammatory disease, cephalosporins for, 714
Penicillin(s), allergy to, alternatives for, 938
antipseudomonal, 679–693
adverse effects of, 686–687
antimicrobial spectrum of, 680–682
clinical pharmacokinetics of, 683–684
clinical use of, 687–690
drug interactions with, 687
empirc therapy with, 689–690
indications, dosing, and preparations of, 684–686
pharmacologic characteristics of, 683
prophylaxis with, 689
safety profile of, 686–687
synergism and antagonism of, 682–683
semi-synthetic, development of, 696
Piperacillin, indications, dosing, and preparations of, 685–686
microbial susceptibility to, 681
pharmacologic characteristics of, 683
with tazobactam, in vitro activity and cost of, 698
indications for, 702
Pleuropulmonary infections, clindamycin for, 852
Pneumocystis carinii infections, clindamycin for, 854
Pneumonia, cephalosporins for, 713–714
community-acquired, in allergic patient, antibiotic therapy for, 937
Pregnancy, clindamycin use in, 855
metronidazole use in, 864
Prostatitis, bacterial, quinolones for, 875–876
Proteus mirabilis, antibiotic susceptibility of, 681
Protozoa, clindamycin spectrum of activity against, 848
metronidazole spectrum of activity against, 858
Pseudomonas, antibiotic susceptibility of, 681
antibiotics for, minimum inhibitory concentrations of, 682
penicillins for, 679–693
Pulmonary infections, cephalosporins for, 713–714
clindamycin for, 852

Quinolones, 869–894
adverse effects of, 886–887
clinical uses of, 874–886
bacterial prostatitis, 875–876
bone/joint infections, 880–881
gastrointestinal infections, 876–878
neutropenia, 883–884
prophylactic, 883–884
respiratory tract infections, 878–880
sexually transmitted diseases, 876
skin infections, 881–883
urinary tract infections, 874–875
drug interactions with, 887–888
pharmacokinetics of, 871–874
in hepatic disease, 907
spectrum of in vitro activity of, 871–872
structure and mechanisms of action of, 870–871
Renal failure, antibiotic dosing in, 919–933
Respiratory tract infections, quinolones for, 878–880
tetracyclines for, 798
Rifampin, in hepatic disease, 914
pharmacokinetics of, 910
Roxithromycin, in hepatic disease, pharmacokinetics of, 909
Sepsis, antibiotic therapy for, in allergic patient, 937
Serratia marcescens, antibiotic susceptibility of, 681
Sexually transmitted diseases, quinolones for, 876
tetracyclines for, 798
Skin/soft tissue infections, cephalosporins for, 713
clindamycin for, 852
quinolones for, 881–883
Streptomycin, dosing of, in renal failure, 921
Sulfa drugs, allergy to, alternatives for, 941

Teicoplanin, 833–844
adverse effects of, 839
antibacterial activity of, vancomycin vs, 835
antimicrobial spectrum of, 833–836
clinical pharmacokinetics of, 836–839
clinical use of, 840–841
dosage recommendations for, 837–838
safety profile of, 839–840
structure of, 834
Tetanus, metronidazole for, 862
Tetracyclines, 789–801
  adverse reactions to, 795–796
  allergy to, alternatives for, 940
  antibiotic sensitivities of, 791
  antimicrobial spectrum of, 790–791
  clinical pharmacokinetics of, 792–794
  clinical use of, 797–798
  dosing recommendations for, 794
  drug interactions with, 796–797
  prophylaxis with, 798
  resistance patterns of, 791–792
  structures of, 790
  treatment with, 798–799
Ticarcillin, indications, dosing, and preparations of, 684–685
  microbial susceptibility to, 681
  pharmacologic characteristics of, 683
  with clavulanic acid, in vitro activity and cost of, 698
  indications for, 702
Tobramycin, chemical configuration of, 764
  dosing of, in renal failure, 921
Toxoplasma infections, clindamycin for, 854
Trichomoniasis, metronidazole for, 863
Trimethoprim-sulfamethoxazole, allergy to, alternatives for, 941

Upper respiratory tract infections, clindamycin for, 851
Ureidopenicillins, antipseudomonal, antimicrobial spectrum of, 680–682
Urinary tract infections, aztreonam for, 740
  quinolones for, 874–875

Vaginosis, bacterial, clindamycin for, 853
  metronidazole for, 863
Vancomycin, 817–831
  allergy to, alternatives for, 941
  antibacterial activity of, teicoplanin vs, 835
  antimicrobial spectrum of, 817–818
  avoidance of, indications for, 828
  clinical spectrum of, 819
  clinical use of, 826–828
  concentrations in body fluids, 823
  drug interactions with, 825–826
  elimination of, 821–822
  in renal failure, dosing of, 921
  peculiarities of, 925
  pharmacokinetics of, 820–823
  in hepatic disease, 910
  resistance potential of, 818–820
  safety profile of, 823–825
  serum concentrations of, 821
  side effects of, 825
  structure of, 834
  therapeutic alternatives to, 828
Volume of distribution, of drugs, in hepatic disease, 897–898

Xanthomonas maltophilia, antibiotic susceptibility of, 681

Zidovudine, in hepatic disease, pharmacokinetics of, 904–905